The CLL patients also have high levels of serum TNF, much of it coming from lymphocytes [36–38], and patients undergoing anti-TNF treatment, such as for rheumatoid arthritis and inflammatory bowel disease have a significantly higher risk of developing lymphomas than normal individuals [39–42]. This evidence concerns the gene TNF and inflammatory bowel disease.